PSI Advisors LLC Has $131,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

PSI Advisors LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 25.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 503 shares of the medical research company’s stock after acquiring an additional 101 shares during the period. PSI Advisors LLC’s holdings in Amgen were worth $131,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Rathbones Group PLC grew its holdings in shares of Amgen by 21.1% during the second quarter. Rathbones Group PLC now owns 11,774 shares of the medical research company’s stock worth $3,679,000 after purchasing an additional 2,054 shares during the last quarter. Quilter Plc lifted its position in Amgen by 1.4% during the 2nd quarter. Quilter Plc now owns 3,749 shares of the medical research company’s stock worth $1,171,000 after buying an additional 50 shares in the last quarter. Brown Brothers Harriman & Co. grew its holdings in Amgen by 21.0% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 20,452 shares of the medical research company’s stock worth $6,390,000 after acquiring an additional 3,555 shares during the last quarter. Fairfield Financial Advisors LTD acquired a new stake in Amgen in the 2nd quarter valued at about $2,528,000. Finally, Capital Wealth Planning LLC raised its stake in shares of Amgen by 47.1% in the second quarter. Capital Wealth Planning LLC now owns 1,226,027 shares of the medical research company’s stock worth $383,072,000 after acquiring an additional 392,727 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of Amgen stock opened at $270.19 on Tuesday. The stock’s fifty day simple moving average is $278.16 and its 200 day simple moving average is $308.35. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market capitalization of $145.24 billion, a PE ratio of 34.60, a PEG ratio of 2.91 and a beta of 0.56. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter last year, the firm posted $4.96 earnings per share. Amgen’s revenue was up 23.2% compared to the same quarter last year. On average, research analysts predict that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.52%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 121.90%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AMGN. Royal Bank of Canada decreased their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Barclays boosted their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Citigroup decreased their price target on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.